Elevating Pharmacists’ Impact on CDK4/6 Inhibitor Therapy for Breast Cancer

Meeting Objectives:

• • Provide an overview of high-risk early breast cancer and HR+/HER2- metastatic breast cancer, emphasizing the current treatment landscape and the role of CDK4/6 inhibitors.
  • Detail the pharmacist’s role in managing and mitigating adverse effects of CDK4/6 inhibitors, including dosing considerations and adjustments, proactive measures, and supportive care strategies.
  • Discuss the pharmacist’s role in collaborative decision-making, personalized therapy selection, and ongoing patient support, including counseling and addressing barriers to adherence.